Bariatrics Clinical Trial - Celgene RPC01-3202

Status:

Open (Study open and enrolling)

ClinicalTrials.gov:

NCT03440385

CONDITION(S): Crohn Disease - TRIAL: Celgene RPC01-3202 - This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect of oral ozanimod as an induction treatment for subjects with moderately to severely active Crohn's Disease.

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease.

Drug

Drug: Ozanimod Other: Placebo

Trial Type

Interventional

Phase

Phase 3

Condition

Chron's Disease

Keywords

Weight loss | Bariatrics